AR and prostate cancer: Furthermore, according to the data by Dehghannasiri and colleagues, up to 10% of prostate cancer fusions involve lncRNAs as the other partner (Dehghannasiri et al., 2019), making it likely that more AR-driven lncRNA fusions will be discovered.